Adcetris Earns Indication for Post Transplant Consolidation

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has expanded the indications for their Hodgkin's lymphoma treatment Adcetris (brentuximab vedotin).

Previously, the FDA had approved Adcetris for two indications: for the treatment of classical Hodgkin lymphoma after failure of auto-hematopoietic stem cell transplantation (HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates, and systemic anaplastic large cell lymphoma (sALCL) in patients who have failed at least one prior multi-agent chemotherapy regimen.

Now, Adcetris has been approved as consolidation therapy.

Specifically, back in February Seattle Genetics submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris seeking approval for the treatment to be used as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin's lymphoma patients who are considered to be at high risk of relapse or disease progression.

This makes Adcetris the first and the only consolidation therapy approved for these patients.

Source: Seattle Genetics

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap